Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IL-21-expanded NK cells for relapsed/refractory AML
NCT02809092Phase 2Unknown
- Sponsor
- Hospital de Clínicas de Porto Alegre
- Start
- Apr 2017
- Primary completion
- Sep 2019
- Countries
- 1
01
Overview
A Phase 2 trial of mbIL21-expanded natural killer cells in acute myeloid leukemia (AML), sponsored by Hospital de Clínicas de Porto Alegre. Status: unknown.
02
Drugs
mbIL21-expanded natural killer cells
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02809092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02809092.